Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Luspatercept yielded high rates of durable transfusion independence in heavily-pretreated, lower-risk MDS.
Luspatercept yielded greater rates of improvement in cell lineages for patients with transfusion-dependent MDS.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
Advertisement
Enrolled patients had non-del(5q) relapsed or refractory disease and were ineligible for erythropoiesis-stimulating agents.
A retrospective study's regression analysis confirmed survival effect of cytarabine-based regimens and allogeneic HSCT.
Inherited thrombocytopenia is associated with risk for myelodysplastic syndromes and malignancies.
A shorter time to response was still observed in the azacitidine plus venetoclax cohort in this retrospective study.
In recent studies, optical genome mapping detected additional genetic aberrations in MDS compared to conventional techniques.
Most patients with MDS achieved an objective response, but limited clinical activity was observed across other blood cancers.
The two-year cumulative incidence of relapse was lower in those who achieved full donor chimerism than in those who didn’t.
“Blood Cancer Talks" hosts are joined by Dr. Stahl to discuss imetelstat and luspatercept treatment for lower-risk MDS.
An analysis of the PEGASUS and PRINCE clinical trials reported long-term efficacy of pegcetacoplan for patients with PNH.
Imetelstat led to significant improvement of red blood cell-transfusion independence rates in patients with lower-risk MDS.
Combination therapies involving PD-1 and CTLA-4 inhibitors exhibited promising activity and tolerability.
Treatment with luspatercept led to significantly less healthcare resource utilization compared with ESAs.
Dr. Raddi discusses his study on identifying predictors of response to ESA therapy in patients with lower-risk MDS.
Compared with epoetin alfa, luspatercept improved transfusion independence and hematological improvement in lower-risk MDS.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.